|
SAB Biotherapeutics, Inc. (SABS) Évaluation DCF |
Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
Pré-Construits Pour Une Utilisation Rapide Et Efficace
Compatible MAC/PC, entièrement débloqué
Aucune Expertise N'Est Requise; Facile À Suivre
SAB Biotherapeutics, Inc. (SABS) Bundle
Explorez les perspectives financières de SAB Biotherapeutics, Inc. (SABS) à l'aide de notre calculatrice DCF conviviale! Entrez vos projections pour la croissance, les marges et les dépenses pour calculer la valeur intrinsèque de SAB Biotherapeutics, Inc. (SABS) et informer vos décisions d'investissement.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 55.2 | 60.9 | 23.9 | 2.2 | 1.3 | .7 | .4 | .2 | .1 | .1 |
| Revenue Growth, % | 0 | 10.21 | -60.73 | -90.63 | -40.94 | -45.52 | -45.52 | -45.52 | -45.52 | -45.52 |
| EBITDA | 21.1 | -15.2 | -15.1 | -38.1 | -42.9 | -.4 | -.2 | -.1 | -.1 | .0 |
| EBITDA, % | 38.26 | -24.96 | -63.26 | -1703.14 | -3244.87 | -49.99 | -49.99 | -49.99 | -49.99 | -49.99 |
| Depreciation | .5 | 1.7 | 3.3 | 3.7 | -8.5 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 0.9924 | 2.72 | 13.77 | 167.28 | -641.77 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 |
| EBIT | 20.6 | -16.9 | -18.4 | -41.9 | -34.4 | -.4 | -.2 | -.1 | -.1 | .0 |
| EBIT, % | 37.27 | -27.68 | -77.03 | -1870.42 | -2603.1 | -53.49 | -53.49 | -53.49 | -53.49 | -53.49 |
| Total Cash | 12.6 | 33.2 | 15.0 | 56.6 | 20.8 | .5 | .3 | .1 | .1 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 20.6 | 8.0 | 5.6 | .0 | .1 | .1 | .1 | .0 | .0 | .0 |
| Account Receivables, % | 37.24 | 13.16 | 23.25 | 0 | 4.16 | 15.56 | 15.56 | 15.56 | 15.56 | 15.56 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Payable | 7.4 | 4.5 | 3.7 | .9 | 1.7 | .3 | .1 | .1 | .0 | .0 |
| Accounts Payable, % | 13.36 | 7.32 | 15.39 | 42.25 | 128.15 | 35.67 | 35.67 | 35.67 | 35.67 | 35.67 |
| Capital Expenditure | -12.7 | -10.9 | -10.9 | -.2 | .0 | -.1 | -.1 | .0 | .0 | .0 |
| Capital Expenditure, % | -23.05 | -17.98 | -45.78 | -8.81 | 0 | -19.12 | -19.12 | -19.12 | -19.12 | -19.12 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | 20.6 | -17.1 | -18.4 | -41.9 | -34.4 | -.4 | -.2 | -.1 | -.1 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -4.8 | -16.8 | -24.4 | -35.5 | -42.2 | -2.0 | -.3 | -.2 | -.1 | -.1 |
| WACC, % | 6.68 | 6.68 | 6.68 | 6.68 | 6.68 | 6.68 | 6.68 | 6.68 | 6.68 | 6.68 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -2.4 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | -1 | |||||||||
| Present Terminal Value | -1 | |||||||||
| Enterprise Value | -3 | |||||||||
| Net Debt | -4 | |||||||||
| Equity Value | 1 | |||||||||
| Diluted Shares Outstanding, MM | 9 | |||||||||
| Equity Value Per Share | 0.10 |
What You Will Get
- Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real SABS financials.
- Real-World Data: Historical data and forward-looking estimates (as indicated in the highlighted cells).
- Forecast Flexibility: Modify forecast assumptions such as revenue growth, EBITDA %, and WACC.
- Automatic Calculations: Instantly observe how your inputs affect SAB Biotherapeutics' valuation.
- Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
- User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step instructions.
Key Features
- Comprehensive Data: SAB Biotherapeutics’ historical financial statements and detailed forecasts.
- Customizable Parameters: Adjust WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Real-Time Insights: Observe the recalculation of SAB Biotherapeutics’ intrinsic value instantly.
- Intuitive Visual Displays: Dashboard charts present valuation results and essential metrics clearly.
- Designed for Precision: A robust tool tailored for analysts, investors, and finance professionals.
How It Works
- 1. Access the Template: Download and open the Excel file containing SAB Biotherapeutics, Inc.'s preloaded data.
- 2. Modify Assumptions: Adjust key parameters such as growth rates, WACC, and capital expenditures.
- 3. View Results Instantly: The DCF model automatically computes the intrinsic value and NPV.
- 4. Explore Scenarios: Analyze various forecasts to evaluate different valuation results.
- 5. Present with Assurance: Deliver professional valuation insights to back your decisions.
Why Choose This Calculator for SAB Biotherapeutics, Inc. (SABS)?
- Designed for Experts: A sophisticated tool tailored for researchers, investors, and industry leaders.
- Comprehensive Data: SAB Biotherapeutics' historical and projected financials integrated for precise analysis.
- Flexible Scenario Analysis: Effortlessly test various forecasts and assumptions.
- Insightful Outputs: Automatically computes intrinsic value, NPV, and essential metrics.
- User-Friendly: Detailed instructions walk you through each step of the calculation.
Who Should Use This Product?
- Investors: Evaluate SAB Biotherapeutics' valuation before making investment decisions.
- CFOs and Financial Analysts: Optimize valuation methodologies and assess future projections.
- Startup Founders: Understand the valuation strategies of leading biotech firms like SAB Biotherapeutics.
- Consultants: Create detailed valuation reports for clients in the biotech sector.
- Students and Educators: Utilize real-world examples to learn and teach valuation practices.
What the Template Contains
- Historical Data: Includes SAB Biotherapeutics' past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate SAB Biotherapeutics' intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of SAB Biotherapeutics' financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.